Lindsay S. Ackerman, MD, FAAD

Emerging Treatments for Atopic Dermatitis

Video content above is prompted by the following:

Are there any ongoing atopic dermatitis studies or emerging therapies that you are excited about?

What advice would you like to share with clinicians taking care of patients with moderate/severe atopic dermatitis?

Videos

Recent advancements in atopic dermatitis research have focused on novel therapies and ongoing clinical trials. Emerging treatments, such as biologics and small molecules, are showing promise in managing moderate to severe cases. Clinicians are advised to stay informed about these developments to optimize patient care. Emphasizing a personalized approach, considering patient-specific factors, and maintaining open communication with patients are crucial. Additionally, integrating new therapies with existing treatment regimens can enhance outcomes. Continuous education and collaboration with specialists are essential for improving management strategies in atopic dermatitis.

Looking to the future of atopic dermatitis treatment, the panel discusses ongoing research and promising emerging therapies. 

Treatment of Bio-Naïve Patients or Those Progressing on Topical or Biologic Atopic Dermatitis Therapy

A bio naïve patient with moderate atopic dermatitis?

A patient whose disease is continuing to progress on topical treatments?

In managing atopic dermatitis, treatment strategies vary based on patient history and disease progression. For a bio-naïve patient with moderate atopic dermatitis, initial treatment typically involves topical therapies, including corticosteroids and calcineurin inhibitors. If the disease progresses despite topical treatments, systemic therapies or phototherapy may be considered. For patients not responding to biologic therapy, switching to an alternative biologic or incorporating adjunctive treatments may be necessary. Treatment plans should be individualized, considering patient-specific factors and potential side effects, to optimize therapeutic outcomes and improve quality of life.

Focusing on clinical scenarios, experts on atopic dermatitis discuss how their treatment approaches vary depending on patient-specific factors.

Use of JAK Inhibitors and Systemic Treatments for Atopic Dermatitis

How widely are clinicians using targeted agents that have become available over the last few years?

Where do you place JAKi vs biologics in the treatment of atopic dermatitis?

When during patient’s treatment journey would you recommend use of JAK inhibitors to your patients?

Who is an ideal candidate for JAKi use in atopic dermatitis?

The integration of targeted agents, including JAK inhibitors (JAKi), in clinical practice for atopic dermatitis has been increasing. Clinicians are evaluating the positioning of JAKi relative to biologics, considering factors such as efficacy, safety, and patient-specific characteristics. JAK inhibitors are often recommended for patients who have not responded adequately to topical treatments or biologics. Ideal candidates for JAKi are those with moderate to severe atopic dermatitis, particularly when rapid symptom control is needed or when other systemic therapies are contraindicated or ineffective.

Dermatologists outline the role of targeted therapies and JAK inhibitors in the treatment of patients with atopic dermatitis.

Long-term Safety of JAK Inhibitors in Atopic Dermatitis

Are there any learnings from long-term upadacitinib data that were not seen in short-term data?

What about short vs long-term data with other JAKi?

How do they impact your use of JAKi for atopic dermatitis?

Long-term data on upadacitinib reveal insights not apparent in short-term studies, particularly regarding sustained efficacy and safety profiles. These findings are crucial for understanding the drug's long-term impact on patients with atopic dermatitis. Comparisons with other JAK inhibitors (JAKi) highlight differences in long-term outcomes, influencing clinical decision-making. The data suggest that while short-term results are promising, long-term data provide a more comprehensive view of treatment benefits and risks. This information is pivotal in guiding the use of JAKi in managing atopic dermatitis over extended periods.

Following a review of findings from the LEVEL UP study, an expert on atopic dermatitis shares what we’ve learned from long-term data on upadacitinib and JAKi.

Lindsay S. Ackerman, MD, FAAD

Articles